 |
|||||
Individual Tests |
|||||
|
|||||
| Code | Test Description * Indicates send out test |
||||
| T716 | Rocky Mountain Spotted Fever (Rickettsia Rickettsii AB) |
||||
|
|||||
| Specimen | 1 ml serum | ||||
|
|||||
| Method | Immunofluorescent assay | ||||
|
|||||
| Schedule | 1–3 days | ||||
|
|||||
| Indication | Exposure to ticks | ||||
|
|||||
| Interpretive Guidelines |
A 2 to 4-fold increase in titer 2 to 4 weeks apart is indicative of disease. | ||||
|
|||||
| Comments | Animals may be negative in early phases of disease. Recommend retest in 2 to 4 weeks if clinical signs persist. | ||||
|
|||||
| * S16740 | Streptococcus Equi ssp. Equi AB | ||||
|
|||||
| Specimen | 1 ml serum | ||||
|
|||||
| Method | ELISA | ||||
|
|||||
| Schedule | 7–10 days | ||||
|
|||||
| * S16792 | Toxoplasma, IgG/IgM | ||||
|
|||||
| Specimen | 1 ml serum | ||||
|
|||||
| Method | ELISA | ||||
|
|||||
| Schedule | 1–7 days | ||||
|
|||||
| Interpretive Guidelines |
A single high IgG does not distinguish prior exposure from a current active infection. Positive IgM titers indicate recent exposure and/or active infection. | ||||
|
|||||
| * S85448 | West Nile Virus AB-SN | ||||
|
|||||
| Specimen | 1 ml serum | ||||
|
|||||
| Method | Serum neutralization | ||||
|
|||||
| Schedule | 7–10 days | ||||
|
|||||
| Indication | Assay detects primarily the IgG response to West Nile virus from natural exposure or vaccination. | ||||
|
|||||
| * S85827 | West Nile Virus AB (IgM Capture ELISA) | ||||
|
|||||
| Specimen | 1 ml serum | ||||
|
|||||
| Method | IgM Capture ELISA | ||||
|
|||||
| Schedule | 3–5 days | ||||
|
|||||
| Indication | Assay detects IgM antibodies indicating recent exposure or vaccination to West Nile virus AB | ||||
|
|||||
| T900 | Sarcocystis Neurona SAG 1 AB (EPM SAG1 AB)–Serum | ||||
|
|||||
| Specimen | 1 ml serum (RT) | ||||
|
|||||
| Method | SAG 1 ELISA | ||||
|
|||||
| Schedule | 1–5 days | ||||
|
|||||
| Comments | This ELISA assay measures antibodies to the primary surface antigen to S. neurona. Titers of 1:100 and greater indicate exposure to S. neurona and possible active disease if associated with clinical signs. Re-evaluation with a convalescent sample in 3 to 4 weeks is indicated with positive results. Negative results in the face of neurologic signs should be repeated in 3 to 4 weeks. Titers may elevate from 1:100 up to 1:3200 with severe infections. The assay can also be used to monitor therapeutic success. | ||||
| T905 | Sarcocystis Neurona SAG 1 AB (EPM SAG1 AB)–CSF | ||||
|
|||||
| Specimen | 2 ml cerebrospinal fluid | ||||
|
|||||
| Method | SAG 1 ELISA | ||||
|
|||||
| Schedule | 1–5 days | ||||
|
|||||
| Comments | Positive CSF titers warrant PCR evaluation for EPM DNA fragments. | ||||
|
|||||
| T910 | EPM SAG1 Antibody Index | ||||
|
|||||
| Tests | EPM SAG1 AB (serum and CSF) Albumin (serum) Microprotein (CSF) EPM SAG1 Antibody Index |
||||
|
|||||
| Specimen | 2 ml serum (RT) and 2 ml cerebrospinal fluid | ||||
|
|||||
| Method | ELISA | ||||
|
|||||
| Schedule | 1–5 days | ||||
|
|||||
| Comments | The SAG1 antibody index is calculated from the SAG 1 titers in serum and CSF compared to the
corresponding albumin levels. An index of >1 is indicative of actual antibody production within the CNS
against S. neurona. CSF anaylsis and microscopic interpretation (CSF) is also recommended with this panel. Please send in an additional or split CSF fluid in a LT with the Equine Pathology Form 7. |
||||
|
|||||
| * S17507 | Sarcocystis Neurona PCR | ||||
|
|||||
| Specimen | 2 ml cerebrospinal fluid | ||||
|
|||||
| Method | PCR | ||||
|
|||||
| Schedule | 7–10 days | ||||
|
|||||
| Comments | The PCR assay is performed on CSF and neural tissue to identify DNA fragments to S. neurona. The assay is run on CSF samples only with a concurrent positive EPM SAG1 AB ELISA result. | ||||
|
|||||
|
|||||
 |
|||||
|
|||||
|
|||||
|
|||||
| Please send comments to the webmaster. ©1997-2008 Antech Diagnostics, Inc. Site design and maintenance by amesDesign. |
|||||
